Filing Flows › Anika Therapeutics (ANIK) › Commercial Channel revenue
Anika Therapeutics (ANIK) Commercial Channel revenue by quarter
Anika Therapeutics' Commercial Channel revenue was $14.0M in Q3 2026 (third quarter 2026), +0.6% from Q2 2026. Over the last 7 quarters it ranged from $11.3M (Q1 2025) to $14.0M (Q3 2026).
| Quarter | Commercial Channel revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $14.0M | +0.6% | +17% |
| Q2 2026 | $13.9M | +11% | +17% |
| Q1 2026 | $12.6M | -5% | +12% |
| Q4 2025 | $13.3M | +11% | — |
| Q3 2025 | $12.0M | +0.8% | — |
| Q2 2025 | $11.9M | +6% | — |
| Q1 2025 | $11.3M | — | — |
Q3 2026 at a glance
Anika Therapeutics, Q3 2026: revenue $30.6M (+10% year over year), operating margin -2.3%, net loss $311K, operating cash flow $8.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Anika Therapeutics' Commercial Channel revenue?
Anika Therapeutics' Commercial Channel revenue was $14.0M in Q3 2026 (third quarter 2026), +0.6% from Q2 2026.
How has Anika Therapeutics' Commercial Channel revenue changed?
Over the last 7 quarters it ranged from $11.3M (Q1 2025) to $14.0M (Q3 2026).